# Scynexis Inc: financial statements, quarterly

SCYX · Nasdaq · CIK 1178253 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/scyx.md) · [Financials](/companies/scyx/financials.md) · [Filings](/companies/scyx/filings.md) · [Insiders](/companies/scyx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/scyx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.8](/filings/0000950170-24-122241.md) | [5.8 d](/filings/0000950170-25-038044.md) | [1.4](/filings/0000950170-25-072548.md) | [0.7](/filings/0000950170-25-107985.md) | [0.7](/filings/0001178253-25-000010.md) | [1.0 d](/filings/0001178253-26-000007.md) | [0.3](/filings/0001178253-26-000011.md) | [1.4](/filings/0001178253-26-000027.md) | [0.3](/filings/0001178253-25-000010.md) | [18.6 d](/filings/0001178253-26-000007.md) | [0.0](/filings/0001178253-26-000011.md) | [0.2](/filings/0001178253-26-000027.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [6.5](/filings/0000950170-24-122241.md) | [10.6 d](/filings/0000950170-25-038044.md) | [7.2](/filings/0000950170-25-072548.md) | [6.8](/filings/0000950170-25-107985.md) | [8.1](/filings/0001178253-25-000010.md) | [4.3 d](/filings/0001178253-26-000007.md) | [5.1](/filings/0001178253-26-000011.md) | [7.1](/filings/0001178253-26-000027.md) | [5.5](/filings/0001178253-25-000010.md) | [4.5 d](/filings/0001178253-26-000007.md) | [12.4](/filings/0001178253-26-000011.md) | [3.9](/filings/0001178253-26-000027.md) |
| Selling, general and administrative | $m | [5.0](/filings/0000950170-24-122241.md) | [3.6 d](/filings/0000950170-25-038044.md) | [3.7](/filings/0000950170-25-072548.md) | [3.2](/filings/0000950170-25-107985.md) | [2.9](/filings/0001178253-25-000010.md) | [4.7 d](/filings/0001178253-26-000007.md) | [3.7](/filings/0001178253-26-000011.md) | [3.8](/filings/0001178253-26-000027.md) | [3.3](/filings/0001178253-25-000010.md) | [3.6 d](/filings/0001178253-26-000007.md) | [4.6](/filings/0001178253-26-000011.md) | [4.1](/filings/0001178253-26-000027.md) |
| Operating income | $m | [(10.1)](/filings/0000950170-24-122241.md) | [(23.1) d](/filings/0000950170-25-038044.md) | [(9.5)](/filings/0000950170-25-072548.md) | [(9.2)](/filings/0000950170-25-107985.md) | [(10.3)](/filings/0001178253-25-000010.md) | [(8.1) d](/filings/0001178253-26-000007.md) | [(8.6)](/filings/0001178253-26-000011.md) | [(9.6)](/filings/0001178253-26-000027.md) | [(8.4)](/filings/0001178253-25-000010.md) | [10.5 d](/filings/0001178253-26-000007.md) | [(16.9)](/filings/0001178253-26-000011.md) | [(7.8)](/filings/0001178253-26-000027.md) |
| Interest expense | $m | [0.2](/filings/0000950170-23-062894.md) | [0.2 d](/filings/0000950170-24-038046.md) | [0.2](/filings/0000950170-24-055590.md) | [0.2](/filings/0000950170-24-093856.md) | [0.2](/filings/0001178253-25-000010.md) | [0.2 d](/filings/0001178253-26-000007.md) | [0.2](/filings/0001178253-26-000011.md) | [0.0](/filings/0001178253-26-000027.md) | [0.0](/filings/0001178253-25-000010.md) | [0.0 d](/filings/0001178253-26-000007.md) | [0.0](/filings/0001178253-26-000011.md) | [0.0](/filings/0001178253-26-000027.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-122241.md) | [0.1 d](/filings/0000950170-25-038044.md) | [0.5](/filings/0000950170-25-072548.md) | [0.0](/filings/0000950170-25-107985.md) | [(0.4)](/filings/0001178253-25-000010.md) | [0.0 d](/filings/0001178253-26-000007.md) | [0.0](/filings/0000950170-25-072548.md) | [0.0](/filings/0000950170-25-107985.md) | [0.0](/filings/0001178253-25-000010.md) | [0.0 d](/filings/0001178253-26-000007.md) | not reported | not reported |
| Net income | $m | [(1.8)](/filings/0000950170-24-122241.md) | [(19.6) d](/filings/0000950170-25-038044.md) | [0.4](/filings/0000950170-25-072548.md) | [(14.5)](/filings/0000950170-25-107985.md) | [(2.8)](/filings/0001178253-25-000010.md) | [(4.4) d](/filings/0001178253-26-000007.md) | [(5.4)](/filings/0001178253-26-000011.md) | [(6.9)](/filings/0001178253-26-000027.md) | [(8.6)](/filings/0001178253-25-000010.md) | [12.3 d](/filings/0001178253-26-000007.md) | [(21.3)](/filings/0001178253-26-000011.md) | [7.4](/filings/0001178253-26-000027.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0000950170-24-122241.md) | not reported | [0.01](/filings/0000950170-25-072548.md) | [(0.30)](/filings/0000950170-25-107985.md) | [(0.06)](/filings/0001178253-25-000010.md) | not reported | [(0.11)](/filings/0001178253-26-000011.md) | [(1.11)](/filings/0001178253-26-000027.md) | [(0.17)](/filings/0001178253-25-000010.md) | not reported | [(0.42)](/filings/0001178253-26-000011.md) | [0.63](/filings/0001178253-26-000027.md) |
| Basic EPS | $ per share | [(0.04)](/filings/0000950170-24-122241.md) | not reported | [0.01](/filings/0000950170-25-072548.md) | [(0.30)](/filings/0000950170-25-107985.md) | [(0.06)](/filings/0001178253-25-000010.md) | not reported | [(0.11)](/filings/0001178253-26-000011.md) | [(1.11)](/filings/0001178253-26-000027.md) | [(0.17)](/filings/0001178253-25-000010.md) | not reported | [(0.42)](/filings/0001178253-26-000011.md) | [0.63](/filings/0001178253-26-000027.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [44.1](/filings/0000950170-23-062894.md) | [34.1](/filings/0000950170-25-038044.md) | [35.5](/filings/0000950170-24-055590.md) | [26.0](/filings/0000950170-24-093856.md) | [28.7](/filings/0000950170-24-122241.md) | [16.1](/filings/0001178253-26-000007.md) | [6.9](/filings/0000950170-25-072548.md) | [11.0](/filings/0000950170-25-107985.md) | [14.8](/filings/0001178253-25-000010.md) | [21.3](/filings/0001178253-26-000027.md) | [36.7](/filings/0001178253-26-000011.md) | [10.5](/filings/0001178253-26-000027.md) |
| Current assets | $m | [129](/filings/0000950170-23-062894.md) | [102](/filings/0000950170-25-038044.md) | [102](/filings/0000950170-24-055590.md) | [94.6](/filings/0000950170-24-093856.md) | [80.5](/filings/0000950170-24-122241.md) | [72.2](/filings/0001178253-26-000007.md) | [52.2](/filings/0000950170-25-072548.md) | [56.5](/filings/0000950170-25-107985.md) | [48.7](/filings/0001178253-25-000010.md) | [40.4](/filings/0001178253-26-000027.md) | [62.7](/filings/0001178253-26-000011.md) | [56.2](/filings/0001178253-26-000027.md) |
| Total assets | $m | [149](/filings/0000950170-23-062894.md) | [128](/filings/0000950170-25-038044.md) | [118](/filings/0000950170-24-055590.md) | [108](/filings/0000950170-24-093856.md) | [99.0](/filings/0000950170-24-122241.md) | [90.6](/filings/0001178253-26-000007.md) | [67.9](/filings/0000950170-25-072548.md) | [60.7](/filings/0000950170-25-107985.md) | [51.1](/filings/0001178253-25-000010.md) | [59.0](/filings/0001178253-26-000027.md) | [77.6](/filings/0001178253-26-000011.md) | [75.0](/filings/0001178253-26-000027.md) |
| Current liabilities | $m | [16.8](/filings/0000950170-23-062894.md) | [16.3](/filings/0000950170-25-038044.md) | [27.3](/filings/0000950170-24-055590.md) | [25.2](/filings/0000950170-24-093856.md) | [25.7](/filings/0000950170-24-122241.md) | [24.1](/filings/0001178253-26-000007.md) | [9.0](/filings/0000950170-25-072548.md) | [10.9](/filings/0000950170-25-107985.md) | [8.5](/filings/0001178253-25-000010.md) | [5.7](/filings/0001178253-26-000027.md) | [15.9](/filings/0001178253-26-000011.md) | [5.8](/filings/0001178253-26-000027.md) |
| Total liabilities | $m | [56.6](/filings/0000950170-23-062894.md) | [55.5](/filings/0000950170-25-038044.md) | [44.1](/filings/0000950170-24-055590.md) | [47.4](/filings/0000950170-24-093856.md) | [40.5](/filings/0000950170-24-122241.md) | [35.6](/filings/0001178253-26-000007.md) | [17.4](/filings/0000950170-25-072548.md) | [16.2](/filings/0000950170-25-107985.md) | [14.6](/filings/0001178253-25-000010.md) | [9.7](/filings/0001178253-26-000027.md) | [36.3](/filings/0001178253-26-000011.md) | [8.0](/filings/0001178253-26-000027.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [92.0](/filings/0000950170-24-122241.md) | [73.0](/filings/0001178253-26-000007.md) | [74.1](/filings/0000950170-25-107985.md) | [60.4](/filings/0001178253-25-000010.md) | [58.5](/filings/0001178253-25-000010.md) | [55.1](/filings/0001178253-26-000027.md) | [50.5](/filings/0001178253-26-000027.md) | [44.5](/filings/0001178253-26-000027.md) | [36.4](/filings/0001178253-25-000010.md) | [49.4](/filings/0001178253-26-000027.md) | [41.3](/filings/0001178253-26-000027.md) | [66.9](/filings/0001178253-26-000027.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [12.4 d](/filings/0000950170-24-122241.md) | [(7.7) d](/filings/0000950170-25-038044.md) | [(4.0)](/filings/0000950170-25-072548.md) | [(10.9) d](/filings/0000950170-25-107985.md) | [0.8 d](/filings/0001178253-25-000010.md) | [(9.9) d](/filings/0001178253-26-000007.md) | [(7.5)](/filings/0001178253-26-000011.md) | [(7.5) d](/filings/0001178253-26-000027.md) | [(8.7) d](/filings/0001178253-25-000010.md) | [18.4 d](/filings/0001178253-26-000007.md) | [(8.1)](/filings/0001178253-26-000011.md) | [(14.9) d](/filings/0001178253-26-000027.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [47.5](/filings/0000950170-23-062894.md) | [47.8](/filings/0000950170-24-055590.md) | [49.9](/filings/0000950170-24-093856.md) | [47.9](/filings/0000950170-24-122241.md) | [48.6](/filings/0000950170-25-072548.md) | [48.5](/filings/0000950170-25-107985.md) | [48.6](/filings/0001178253-25-000010.md) | [49.4](/filings/0001178253-26-000011.md) | [6.2](/filings/0001178253-26-000027.md) | [49.9](/filings/0001178253-25-000010.md) | [51.0](/filings/0001178253-26-000011.md) | [11.8](/filings/0001178253-26-000027.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,949,609 at 2026-08-01, from the cover of the [10-Q filed 2026-08-10](/filings/0001178253-26-000027.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.